Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: A retrospective cohort study

HIV Medicine

Volumn 13, Issue 6, 2012, Pages 337-344

  Hermans, S M ^a,b,c   van Leth, F ^b,d   Manabe, Y C ^a,e   Hoepelman, A I M ^c   Lange, J M A ^b   Kambugu, A ^a  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Baseline CD4 cell count; Mortality; Resource limited setting; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE FINDING; CD4 LYMPHOCYTE COUNT; EARLY INTERVENTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; TUBERCULOSIS; UGANDA; URBAN POPULATION;

EID: 84861818160     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00980.x     Document Type: Article

References (34)

1. Egger M, May M, Chêne G etal. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
2. Sterne JAC, Hernán MA, Ledergerber B etal. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-384.
3. Sterne JA, May M, Costagliola D etal. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
4. Sabin C. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19: 1995-2000.
5. Kitahata MM, Gange SJ, Abraham AG etal. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
6. Severe P, Juste MA, Ambroise A etal. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-265.
7. Emery S, Neuhaus JA, Phillips AN etal. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-1144.
8. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2011.
9. World Health Organization. Rapid Advice: Antiretroviral therapy for HIV infection in adults and adolescents, 2009.
10. Mills EJ, Bakanda C, Birungi J etal. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25: 851-855.
11. Braitstein P, Brinkhof MW, Dabis F etal. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
12. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-1908.
13. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49: 965-972.
14. Ministry of Health, Uganda. National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents, and Children, 2008.
15. Ministry of Health, Uganda. National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents, and Children, 2009.
16. World Health Organization. Treatment of Tuberculosis Guidelines, 2010.
17. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AIM, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS ONE 2010; 5: e10527.
18. Muwanga A, Easterbrook P, Schaefer P etal. Losses to Follow-up in a Large ART Program in Uganda. Conference of Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 840].
19. Keiser O, Anastos K, Schechter M etal. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13: 870-879.
20. Cornell M, Grimsrud A, Fairall L etal. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24: 2263-2270.
21. Boulle A, Van Cutsem G, Hilderbrand K etal. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24: 563-572.
22. Wools-Kaloustian K, Kimaiyo S, Musick B etal. The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. AIDS 2009; 23: 195-201.
23. Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE 2010; 5: e13268.
24. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Annual Report. 2005.
25. Geng EH, Bwana MB, Kabakyenga J etal. Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-Infected ART-Eligible patients in Uganda. PLoS ONE 2010; 5: e14098.
26. Tuboi SH, Schechter M, McGowan CC etal. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51: 615-623.
27. Tuboi SH, Brinkhof MW, Egger M etal. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-Infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45: 52-59.
28. Babigumira JB, Castelnuovo B, Stergachis A etal. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS ONE 2011; 6: e18193.
29. Brinkhof MW, Egger M, Boulle A etal. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521.
30. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 437-444.
31. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
32. Hanson DL, Chu SY, Farizo KM, Ward JW, Adult and Adolescent Spectrum of HIV Disease Project Group. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome - defining and other human immunodeficiency virus - related illnesses. Arch Intern Med 1995; 155: 1537-1542.
33. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009; 4: e5790.
34. Egger M, Spycher BD, Sidle J etal. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011; 8: e1000390.